Hauptinhalt
Wissenschaftliche Veröffentlichungen mit Beteiligung der Urologischen Universitätsklinik Marburg
2023
1. P Karschuck, L Müller, C Groeben, C Aksoy, L Flegar, A Zacharis, M Baunacke, C Wülfing, J Huber (in press) Patientenveranstaltungen in der deutschen Urologie: Trend zu Hybrid-Formaten? Urologie; doi: 10.1007/s00120-023-02162-w (Impact Factor 2022: 0.6)
2. C Aksoy, A Zacharis, C Groeben, P Karschuck, L Flegar, M Baunacke, C Thomas, M Schmidt, J Huber (2023) Entwicklung der Zirkumzisionszahlen in Deutschland seit Billigung der rituellen Beschneidung: Eine bevölkerungsbezogene Analyse von 2013 bis 2018. Urologie 62: 711-714 (Impact Factor 2022: 0.6)
3. H Haas*, L Müller*, T Speck, MS Michel, J Huber (2023) Versorgungsstruktur der ambulanten Urologie in Deutschland Urologie 62: 503-509(Impact Factor 2022: 0.6)
4. R Herout, M Baunacke, L Flegar, A Borkowetz, A Reicherz, R Koch, K Kraywinkel, C Thomas, C Groeben, J Huber (2023) Upper Tract Urothelial Carcinoma in Germany: Epidemiological Data and Surgical Treatment Trends in a Total Population Analysis from 2006 to 2019. World J Urol 41: 127-133 (Impact Factor 2022 3.4)
5. L Flegar, SG Thoduka, D Libbrizzi, M Luster, A Zacharis, H Heers, N Eisenmenger, H Ahmadzadehfar, M Eiber, W Weber, C Groeben, J Huber (2023) Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020. Eur J Nucl Med Mol Imaging 50: 2188-2195 (Impact Factor 2021 10.1)
6. A Zacharis, P Reimold, J Beckmann, J Jung, T Martin, N Eisenmenger, C Aksoy, SG Thoduka, C Groeben, J Huber, L Flegar (in press) Trends in renal transplantation and living donor nephrectomy in Germany: a total population analysis in Germany from 2006 to 2021. World J Urol xx: (Impact Factor 2018: 2.8)
7. C Aksoy, P Reimold, P Karschuck, C Groeben, R Koch, N Eisenmenger, S Thoduka, A Zacharis, H Schmelz, J Huber, L Flegar (in press) Trends in the use of testicular prostheses in Germany: A total population analysis from 2006-2021. Andrology (Impact factor 2022: 4.6)
8. P Reimold, C Aksoy, J Beckmann, A Zacharis, C Groeben, P Karschuck, N Eisenmenger, J Geks, J Huber, L Flegar (in press) Development and outcomes of surgical and urological kidney transplantation programs in Germany: a total population analysis from 2006 to 2021. World J Urol xx: (Impact Factor 2018: 2.8)
9. L Flegar, J Huber, J Putz, C Thomas, H Apel, B Wullich, F Friedersdorff, S Hauser, M Ritter, K Kernig, K Weigand, H Heynemann, M Stöckle, P Zeuschner (in press) Multicenter evaluation of complex urinary diversion for renal transplantation: outcomes of creative surgical solutions. World J Urol (Impact Factor 2022: 3.4)
10. A Ihrig, PM Pernt, S Zschäbitz, J Huber, H-C Friederich, TJ Bugaj, I Maatouk (in press) Neurocognitive effects of androgen deprivation therapy and new hormonal agents in a sample of patients with metastatic prostate cancer. Int Urol Nephrol doi: 10.1007/s11255-023-03712-z. (Impact Factor 2022: 2.0)
11. Gandaglia G, Pellegrino F, Golozar A, De Meulder B, Abbott T, Achtman A, Imran Omar M, Alshammari T, Areia C, Asiimwe A, Beyer K, Bjartell A, Campi R, Cornford P, Falconer T, Feng Q, Gong M, Herrera R, Hughes N, Hulsen T, Kinnaird A, Lai LYH, Maresca G, Mottet N, Oja M, Prinsen P, Reich C, Remmers S, Roobol MJ, Sakalis V, Seager S, Smith EJ, Snijder R, Steinbeisser C, Thurin NH, Hijazy A, van Bochove K, Van den Bergh RCN, Van Hemelrijck M, Willemse PP, Williams AE, Zounemat Kermani N, Evans-Axelsson S, Briganti A, N’Dow J; PIONEER Consortium (in press) Clinical Caracterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data. Eur Urol. doi: 10.1016/j.eururo.2023.06.012 (Impact Factor 2022: 23.4)
12. B Hoeh, CC Garcia, S Banek, N Klümper, A Cox, J Ellinger, P Schmucker, O Hahn, A Mattigk, F Zengerling, P Becker, K Erdmann, BT Buerk, L Flegar, J Huber, C Kalogirou, P Zeuschner (2023) Early CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicenter real-world experience applying different CRP kinetics definitions. Clinical & Translational Immunology 12: e1471 (Impact Factor 2022: 5.8)
13. Siltari A, Lönnerbro R, Pang K, Shiranov K, Asiimwe A, Evans-Axelsson S, Franks B, Kiran A, Murtola TJ, Schalken J, Steinbeisser C, Bjartell A, Auvinen A; PIONEER Consortium (2023) How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis. Clin Genitourin Cancer 21: 316.e1-316.e11 (Impact Factor 2022: 3.2)
14. M Baunacke, E Abbate, N Eisenmenger, U Witzsch, A Borkowetz, J Huber, C Thomas, J Putz (2023) Insufficient utilization of care in male incontinence surgery: Health care reality in Germany from 2006 to 2020 and a systematic review of the international literature. World J Urol 41: 1813-1819 (Impact Factor 2022: 3.4)
15. TJ Bugaj, I Maatouk, T Hanslmeier, S Zschäbitz, J Huber, C Flock, H-C Friederich, A Ihrig (2023) Couples Coping with Advanced Prostate Cancer: An Explorative Study on Decision-Making Preferences, Self-Efficacy and Fear of Progression. World J Urol 41: 1041-1046 (Impact Factor 2022: 3.4)
16. L Flegar, SG Thoduka, AH Mahnken, J Figiel, H Heers, C Aksoy, N Eisenmenger, C Groeben, J Huber, A Zacharis (2023) Focal therapy for renal cancer: comparative trends in the United States and Germany from 2006 to 2020 and analysis of the German health care landscape. Urol Int 107: 396-405 (Impact Factor 2022: 1.6)
17. C Groeben, K Boehm, R Koch, U Sonntag, T Nestler, J Struck, M Heck, M Baunacke, A Uhlig, M Koelker, CP Meyer, B Becker, J Salem, J Huber, M Leitsmann (2023) Hospital rating websites play a minor role for uro-oncologic patients when choosing a hospital for major surgery: Results of the German multicenter NAVIGATOR-study. World J Urol 41: 601-609 (Impact Factor 2022: 3.4)
18. H Heers, MC Butea-Bocu, C Groeben, J Huber, B Wullich, PJ Goebell, C Fiebig (in press) Geriatrisches Assessment – Was sollte vor Therapiebeginn des mHSPC und des mCRPC gemacht und bedacht werden? Akt Urol: doi: 10.1055/a-2155-1944 (Impact Factor 2022: 0.3)
19. J Huber, H Borgmann, K Miller, AS Merseburger, S Krege, C Gratzke (2023) Urologie 2030: Die dringende Notwendigkeit die Digitalisierung in der Urologie schon jetzt voranzutreiben um die medizinische Versorgung aufrecht erhalten zu können – ein Expertenkonsens Akt Urol 54: 213-219 (Impact Factor 2022: 0.3)
20. A Ihrig, PM Pernt, S Zschäbitz, J Huber, HC Friederich, TJ Bugaj, I Maatouk (in press) Response to the letter to editor: Neurocognitive deficits attributed to androgen deprivation therapy in patients with prostate cancer should be reconsidered. Int Urol Nephrol 2023 Sep 12. doi: 10.1007/s11255-023-03787-8. (Impact Factor 2022: 2.0)
21. M Giese, M Butea-Bocu, J Huber, C Groeben (in press) Prähabilitation bei radikaler Zystektomie. Urologie: doi: 10.1007/s00120-023-02172-8 (Impact Factor 2022: 0.6)
22. C Doehn, J Huber, J Klier (2023) Urologische Versorgungsforschung in Deutschland: Auf einem guten Weg! Akt Urol 54: 1-2 (Impact Factor 2022: 0.3)
23. K Kraywinkel, L Flegar, J Huber, C Groeben (2023) Krebsregister in Deutschland: Was bringt die Zukunft für die Urologie? Akt Urol 54: 208-212 (Impact Factor 2022: 0.3)
24. Omar MI, MacLennan S, Ribal MJ, Roobol MJ, Dimitropoulos K, van den Broeck T, MacLennan SJ, Axelsson SE, Gandaglia G, Willemse PP, Mastris K, Ransohoff JB, Devecseri Z, Abbott T, De Meulder B, Bjartell A, Asiimwe A, N'Dow J; PIONEER Consortium (2023) Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium. Nat Rev Urol 20: 494-501 (Impact Factor 2022: 15.3)
25. C Aksoy, P Karschuck, M Derigs, S Sevinc, C Groeben, A Zacharis, L Flegar, A Pehl, J Huber, S Mandal (2023) Successful management of 30 kg gigantic para-testicular liposarcoma. BMC Urol 23: 92 (Impact Factor 2022: 2.0)
26. C Volberg, S Schrade, H Heers, AJP Carrasco, A Morin, M Gschnell (2023) Wünsche und Vorsorgeplanung für das Lebensende von Patienten mit fortgeschrittenem Hautkrebs. J Dtsch Dermatol Ges 21(10):1148-1156
27. S Zschäbitz, N Biernath, T Hilser, A Höllein, F Zengerling, J Casuscelli, P Paffenholz, D Seidl, C Lutz, K Schlack, D Kingreen, N Klümper, P Ivanyi, G von Amsberg, H Heers, F Roghmann, RL Tauber, R Cathomas, L Hofer, G Niegisch, M Klee, R Ehrenberg, A Hassler, BA Hadaschik, V Grünwald, C Darr (2023) Enfortumab Vedotin in metastatic urothelial carcinoma: Survival and safety in a European multicenter real-world patient cohort. Eur Urol Open Sci 53:31-37
28. F Kullmann, PL Strissel, R Strick, R Stoehr, M Eckstein, S Bertz, B Wullich, D Sikic, S Wach, H Taubert, P Olbert, H Heers, MF Lara, ML Macias, E Matas-Rico, MJ Lozano, D Prieto, I Hierro, T van Doeveren, I Bieche, J Masliah-Planchon, R Beaurepere, JL Boormans, Y Allory, B Herrera-Imbroda, A Hartmann, V Weyerer (2023, in review) Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: Comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected multi-institutional cohort. J Clin Pathol 76(2):126-132
29. T Boeselt, P Terhorst, J Kroenig, C Nell, M Spielmanns, U Boas, M Veith, C Vogelmeier, T Greulich, AR Koczulla, B Beutel, J Huber, H Heers (2023, in review) Specific molecular peak analysis by ion mobility spectrometry of volatile organic compounds in urine of COVID-19 patients: A novel diagnostic approach. Journal of Virological Methods
30. C Volberg, F Urhahn, AJP Carrasco, A Morin, M Gschnell, J Huber, L Flegar, H Heers (2023, in review) End of life care preferences of patients with advanced urologic malignancies: An explorative survey study at a tertiary referral center. Palliative and Supportive care
31. Pavlakis E, Neumann M, Merle N, Wieboldt R, Wanzel M, Ponath V, Pogge von Strandmann E, Elmshäuser S, Stiewe T. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis. J Exp Clin Cancer Res. 2023 Aug 10;42(1):203. doi: 10.1186/s13046-023-02785-z. PMID: 37563605; PMCID: PMC10413714.
32. Hänze J, Schulte-Herbrüggen J, Hofmann R, Hegele A. (2023) Modulation of immune checkpoint regulators in interferon γ induced urothelial carcinoma and activated T-lymphocyte cells by cytostatics. Genes Immun. 24:149-153. doi: 10.1038/s41435-023-00203-0. (Impact Factor 2022: 5.0)
2022
1. Aksoy C, Ihrig A, Reimold P, Tosev G, Himmelsbach R, Jesser J, Babayigit G, Huber J. Better Knowledge about Testicular Cancer Might Improve the Rate of Testicular (Self-)Examination: A Survey among 1,025 Medical Students in Germany. Urol Int. 2022;106(10):1056-60. Epub 2022/07/29. doi: 10.1159/000525854. PubMed PMID: 35901778; PubMed Central PMCID: PMCPMC9677845.
2. Bonaterra GA, Schleper A, Skowronek M, Kilian LS, Rink T, Schwarzbach H, Heers H, Hänze J, Rexin P, Ramaswamy A, Denkert C, Wilhelm B, Hegele A, Hofmann R, Weihe E, Kinscherf R. Increased Density of Growth Differentiation Factor-15+ Immunoreactive M1/M2 Macrophages in Prostate Cancer of Different Gleason Scores Compared with Benign Prostate Hyperplasia. Cancers (Basel). 2022;14(19). Epub 2022/10/15. doi: 10.3390/cancers14194591. PubMed PMID: 36230513; PubMed Central PMCID: PMCPMC9578283.
3. Borkowetz A, Leitsmann M, Baunacke M, Borgmann H, Böhm K, Groeben C, Roigas J, Schneider A, Speck T, Volkmer B, Witzsch U*, Huber J*. Akzeptanz und Stand der Digitalisierung in Klinik und Praxis. Die Urologie. 2022;61(12):1365-72. doi: 10.1007/s00120-022-01889-2.
4. Derigs M, Heers H, Lingelbach S, Hofmann R, Hänze J. Soluble PD-L1 in blood correlates positively with neutrophil and negatively with lymphocyte mRNA markers and implies adverse sepsis outcome. Immunol Res. 2022;70(5):698-707. Epub 2022/06/23. doi: 10.1007/s12026-022-09302-y. PubMed PMID: 35732880; PubMed Central PMCID: PMCPMC9499885.
5. Flegar, L., Zacharis, A., Aksoy, C., Heers, H., Derigs, M., Eisenmenger, N., Borkowetz, A., Groeben, C. & Huber J.. Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2019. World J Urol. 2022;40(7):1715-21. Epub 2022/04/30. doi: 10.1007/s00345-022-04017-z. PubMed PMID: 35486177; PubMed Central PMCID: PMCPMC9237006.
6. Flegar L, Thoduka SG, Mahnken AH, Figiel J, Heers H, Aksoy C, Eisenmenger N, Groeben C, Huber J, Zacharis A. Focal therapy for renal cancer: comparative trends in the United States and Germany from 2006 to 2020 and analysis of the German health care landscape. World Journal of Urology. 2022;volume 40: 1645–52.
7. Flegar, L., Zacharis, A., Aksoy, C., Heers, H., Derigs, M., Eisenmenger, N., Borkowetz, A., Groeben, C. & Huber J. Alternative- and focal therapy trends for prostate cancer: a total population analysis of in-patient treatments in Germany from 2006 to 2019. World J Urol. 2022;40(7):1645-52. Epub 2022/05/14. doi: 10.1007/s00345-022-04024-0. PubMed PMID: 35562598; PubMed Central PMCID: PMCPMC9236973.
8. Heers H, Stay D, Wiesmann T, Hofmann R. Urolithiasis in Germany: Trends from the National DRG Database. Urol Int. 2022;106(6):589-95. Epub 2021/12/10. doi: 10.1159/000520372. PubMed PMID: 34883491; PubMed Central PMCID: PMCPMC9248299.
9. Herout R, Baunacke M, Flegar L, Borkowetz A, Reicherz A, Koch R, Kraywinkel K, Thomas C, Groeben C, Huber J. Upper tract urothelial carcinoma in Germany: epidemiological data and surgical treatment trends in a total population analysis from 2006 to 2019. World Journal of Urology. 2022. doi: 10.1007/s00345-022-04219-5.
10. Keber CU, Derigs M, Schultz C, Wegner M, Lingelbach S, Wischmann V, Hofmann R, Denkert C, Hegele A, Hänze J. Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood. Cancer Immunol Immunother. 2022;71(10):2381-9. Epub 2022/02/21. doi: 10.1007/s00262-022-03166-9. PubMed PMID: 35184226; PubMed Central PMCID: PMCPMC9463294.
11. Köther AK, Büdenbender B, Grüne B, Holbach S, Huber J, von Landenberg N, Lenk J, Martini T, Michel MS, Kriegmair MC, Alpers GW. Different patients, different preferences: A multicenter assessment of patients' personality traits and anxiety in shared decision making. Cancer Med. 2022;11(15):2999-3008. Epub 2022/03/25. doi: 10.1002/cam4.4667. PubMed PMID: 35322925; PubMed Central PMCID: PMCPMC9359866.
12. Leuchtweis I, Groeben C, Flegar L, Zacharis A, Baunacke M, Thomas C, Schmidt M, Schneider A, Schultz-Lampel D, Volkmer B, Eisenmenger N, Salem N, Huber J. Ambulant vor stationär? – Versorgungswirklichkeit und ökonomische Analyse von kleinen urologischen Eingriffen in Deutschland von 2013 bis 2018. Die Urologie. 2022;61(11):1229-36. doi: 10.1007/s00120-022-01873-w.
13. Sauer C, Ihrig A, Hanslmeier T, Huber J, Hiller K, Friederich H-C, Maatouk I. Health-related quality of life of advanced prostate cancer patients and spouses: results from actor-partner interdependence models. Supportive Care in Cancer. 2022;30(8):6985-93. doi: 10.1007/s00520-022-07100-8.
14. Uhlig A, Baunacke M, Groeben C, Borkowetz A, Volkmer B, Ahyai SA, Trojan L, Eisenmenger N, Thomas C, Huber J *, M Leitsmann* [Contemporary surgical management of benign prostatic obstruction in Germany : A population-wide study based on German hospital quality report data from 2006 to 2019]. Urologe A. 2022;61(5):508-17. Epub 2022/02/18. doi: 10.1007/s00120-022-01777-9. PubMed PMID: 35174398; PubMed Central PMCID: PMCPMC9072522.
15. Wessendorf J, König AM, Heers H, Mahnken AH. Efficacy and Safety of Combined Embolization and Radiofrequency Ablation in Stage 1 Renal Cell Carcinomas. Rofo. 2022;194(9):1020-5. Epub 2022/03/11. doi: 10.1055/a-1770-4724. PubMed PMID: 35272357.
16. Wolff I, Burchardt M, Gilfrich C, Peter J, Baunacke M, Thomas C, Huber J, R Gillitzer, Sikic D, Fiebig C, Steinestel J, Schifano P, Löbig N, Bolenz C, Distler FA, Hüttenbrink C, Janssen M, Schilling D, Barakat B, Harke NN, Fuhrmann C, Manseck A, Wagenhoffer R, Geist E, Blair L, Pfitzenmaier J, Reinhardt B, Hoschke B, Burger M, Bründl J, Schnabel MJ, May M, IMPROVE study group. Patients Regret Their Choice of Therapy Significantly Less Frequently after Robot-Assisted Radical Prostatectomy as Opposed to Open Radical Prostatectomy: Patient-Reported Results of the Multicenter Cross-Sectional IMPROVE Study. Cancers. 2022;14(21):5356. PubMed PMID: doi:10.3390/cancers14215356.